DexCom (DXCM) Trading at $64.62 with P/E Ratios 30.92 and 25.91
Published on 4/26/2026

AI Summary
DexCom, Inc. (DXCM) shares traded at $64.62 as of April 20th. The company reported trailing and forward P/E ratios of 30.92 and 25.91, respectively. DexCom has achieved an average revenue growth of 17.4% annually over the past three years, with projections suggesting 15.2% growth ahead. The launch of the Stelo over-the-counter CGM and the G7 15-day sensor is expected to expand the market and improve gross margins to 63-64%, potentially increasing user retention and capturing millions of new insured lives. DexCom is targeting aggressive growth in international markets, particularly in Western Europe, Japan, and Australia.
Related News

Earnings
Oracle (ORCL) Q3 Earnings Exceed Expectations, Contract Pipeline at $638B
Jun 10

Earnings
Oracle (ORCL) plans $20 billion raise amid AI spending concerns
Jun 10

Earnings
Lululemon (LULU) Reports $2.5B Revenue Growth but Low EPS Guidance
Jun 10

Markets
Home Depot (HD) Stock Analysis: 3% Yield and 20 P/E Ratio
Jun 10